scholarly journals Host Immunological Effects of Partial Splenic Embolization in Patients with Liver Cirrhosis

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Yasushi Matsukiyo ◽  
Hidenari Nagai ◽  
Teppei Matsui ◽  
Yoshinori Igarashi
Keyword(s):  
Liver Cirrhosis ◽  
Japanese Patients ◽  
Serum Levels ◽  
Treg Cells ◽  
Host Immunity ◽  
Th2 Cells ◽  
Partial Splenic Embolization ◽  
T Lymphocyte Subsets ◽  
Splenic Embolization ◽  
Significant Change

Purpose. Restoration of the balance between T lymphocyte subsets and between Th1/Th2 cytokines together with improvement of antitumor immunity has been reported after hepatosplenectomy in patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC). However, the detailed effects of partial splenic embolization (PSE) on host immunity are unknown. Accordingly, this study evaluated host immunity in patients with cirrhosis receiving PSE for thrombocytopenia.Methods. Twenty-three adult Japanese patients with cirrhosis and thrombocytopenia underwent PSE using straight coils at our hospital between 2010 and 2015. Blood samples were collected before PSE and 4 weeks after PSE.Results. The platelet counts were significantly higher 4 weeks after PSE compared with before PSE. The white blood cell count (neutrophils, lymphocytes, and monocytes) also increased significantly after PSE. Furthermore, Th1 cells and Th2 cells showed a significant increase at 4 weeks after PSE compared with before PSE, although there was no significant change of Treg cells. Moreover, serum levels of TNF-alpha, soluble TNF receptor I, and soluble Fas were significantly increased after PSE. There was no significant change of the Child-Pugh score.Conclusions. In patients with cirrhosis and thrombocytopenia, PSE not only promoted the recovery of leukopenia and thrombocytopenia but also induced activation of host immunity.

scholarly journals Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Hidenari Nagai ◽  
Takanori Mukozu ◽  
Daigo Matsui ◽  
Takenori Kanekawa ◽  
Masahiro Kanayama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Liver Cirrhosis ◽  
Antitumor Immunity ◽  
Host Immunity ◽  
Th2 Cells ◽  
Host Immune System ◽  
Advanced Hepatocellular Carcinoma ◽  
Before And After ◽  
Significant Change

Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy.Methods. Forty-five adult Japanese LC patients received sorafenib for aHCC between 2009 and 2011 at our hospital. Sorafenib was administered at a dose of 200–800 mg/day for 4 weeks. Blood samples were collected before and after treatment.Results. Eleven patients were treated with sorafenib at 200 mg/day (200 group), 27 patients received sorafenib at 400 mg/day (400 group), and 7 patients were given sorafenib at 800 mg/day (800 group). There was no significant change in the percentage of Th1 cells after treatment in any group. However, the percentages of Th2 cells and regulatory T cells were significantly decreased after treatment in the 400 group and 800 group compared with before treatment, although there was no significant change after treatment in the 200 group.Conclusions. These results indicate that treatment with sorafenib might induce Th1 dominance and prevent the escape of tumor cells from the host immune system in LC patients with aHCC.

scholarly journals Sustained viral response (SVR) in type C liver cirrhosis patients undergoing peginterferon α-2b/ribavirin combination therapy after partial splenic embolization

Kanzo ◽  
2011 ◽  
Vol 52 (1) ◽  
pp. 26-35
Author(s):  
Keisuke Shiina ◽  
Atsushi Naganuma ◽  
Tomofumi Takakusaki ◽  
Masashi Namikawa ◽  
Hiroki Tahara ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Combination Therapy ◽  
Sustained Viral Response ◽  
Partial Splenic Embolization ◽  
Viral Response ◽  
Splenic Embolization ◽  
Type C ◽  
Peginterferon Α

Partial splenic embolization in patients with liver cirrhosis and hepatocellular carcinoma: Effects on portal hemodynamics

1994 ◽  
Vol 1 (2) ◽  
pp. 172-175 ◽  
Author(s):  
Kazuhiro Yamashiro ◽  
Mitsuhiro Mukaiya ◽  
Hiromichi Kimura ◽  
Tadashi Katsuramaki ◽  
Kazuaki Sasaki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Partial Splenic Embolization ◽  
Portal Hemodynamics ◽  
Splenic Embolization

631 THE EFFECT OF PARTIAL SPLENIC EMBOLIZATION FOR THROMBOCYTOPENIA IN LIVER CIRRHOSIS PATIENTS

2012 ◽  
Vol 56 ◽  
pp. S250 ◽  
Author(s):  
B.I. Kim ◽  
Y.K. Cho ◽  
H.J. Kim ◽  
J.H. Park ◽  
D.I. Park ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Partial Splenic Embolization ◽  
Splenic Embolization

scholarly journals Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Yoshihiko Ooka ◽  
Tetsuhiro Chiba ◽  
Sadahisa Ogasawara ◽  
Tenyu Motoyama ◽  
Eiichiro Suzuki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Failure ◽  
Transarterial Chemoembolization ◽  
Systemic Chemotherapy ◽  
Serum Levels ◽  
Severe Thrombocytopenia ◽  
Partial Splenic Embolization ◽  
Long Term Effects ◽  
Platelet Counts ◽  
Splenic Embolization

Background. Thrombocytopenia often makes the introduction of systemic treatment difficult in patients with cirrhosis and hepatocellular carcinoma (HCC). We retrospectively evaluated the long-term effects of partial splenic embolization (PSE) with transarterial chemoembolization (TACE) in patients with HCC patients accompanied by thrombocytopenia.Patients and Methods. Twenty-one patients with HCC complicated by severe thrombocytopenia (platelet count, <5.0 × 104/mm3) were treated with PSE and TACE. Both the safety and platelet-increasing effect was evaluated in these patients.Results. Seventeen of 21 patients (81.0%) showed increased platelet counts to ≥5.0 × 104/mm3. Subsequently, 13 patients (61.9%) successfully received systemic chemotherapy. Platelet counts and serum levels of total bilirubin, as well as neutrophil counts, improved significantly one month after treatment. However, serum levels of albumin and hemoglobin decreased significantly one month after treatment. Severe adverse events, including acute liver failure and portal vein thrombus, were observed in two patients.Conclusion. PSE with selective TACE made it possible for patients with HCC and severe thrombocytopenia to receive systemic chemotherapy. Although PSE with TACE was safe and tolerable for most patients, the extent of PSE with TACE in a wide area of the liver may increase the risk for fatal liver failure.

scholarly journals Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia

2019 ◽  
Vol 47 (6) ◽  
pp. 2555-2561 ◽  
Author(s):  
Hongtu Wu ◽  
Xian Ding ◽  
Deyu Zhao ◽  
Yong Liang ◽  
Wei Ji
Keyword(s):  
Peripheral Blood ◽  
Inflammatory Responses ◽  
Cell Subset ◽  
Serum Levels ◽  
Treg Cells ◽  
Control Group ◽  
T Lymphocyte Subsets ◽  
Mycoplasma Pneumonia ◽  
Peripheral Blood Lymphocyte Subset ◽  
Ifn Γ

Objective To study the effect of the leukotriene receptor agonist montelukast combined with methylprednisolone on inflammatory response and peripheral blood lymphocyte subset content in children with mycoplasma pneumonia. Methods Seventy-four children were enrolled and randomly divided into a standard treatment group and a montelukast plus methylprednisolone group. Serum levels of inflammatory cytokines and corresponding cytokines of T lymphocyte subsets were measured, and peripheral blood was collected to determine the T cell subset content. Results At 3 days and 7 days after treatment, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly decreased in both groups, while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly increased. However, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly lower while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly higher in the montelukast plus methylprednisolone group compared with the control group. Conclusion Montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia can inhibit inflammatory responses and regulate levels of Th1/Th2 and Th17/Treg cells.

Partial Splenic Embolization for Hypersplenism in Cirrhotic Patients. A Case Series

2014 ◽  
Vol 23 (2) ◽  
pp. 215-218 ◽  
Author(s):  
Secil Omer ◽  
Octavian Zara ◽  
Claudia Iacobescu ◽  
Ion Dina
Keyword(s):  
Liver Cirrhosis ◽  
Portal Hypertension ◽  
Interventional Procedure ◽  
Case Series ◽  
Favourable Outcome ◽  
High Morbidity ◽  
Severe Thrombocytopenia ◽  
Partial Splenic Embolization ◽  
Splenic Embolization ◽  
Prognosis Of Liver Cirrhosis

The prognosis of liver cirrhosis depends on the presence of its major complications as well as on other factors such as hypersplenism with thrombocytopenia. Partial splenic embolization is an effective interventional procedure performed in liver cirrhosis complicated with portal hypertension to improve the low platelet count. This technique represents an efficient alternative to splenectomy, which has major drawbacks and is associated with a high morbidity. We report a series of patients with liver cirrhosis and portal hypertension who presented with severe thrombocytopenia and were treated with partial splenic embolization eventually having a favourable outcome.

Risk factors for complications after partial splenic embolization for liver cirrhosis

2008 ◽  
Vol 95 (6) ◽  
pp. 744-750 ◽  
Author(s):  
H. Hayashi ◽  
T. Beppu ◽  
K. Okabe ◽  
T. Masuda ◽  
H. Okabe ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Cirrhosis ◽  
Partial Splenic Embolization ◽  
Splenic Embolization
Sign in / Sign up

Export Citation Format

Share Document